GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 252 Directors: GSK India Leadership Team: Mr. R. Krishnaswamy # (upto January 27, 2021) Mr. A. Kashyap (w.e.f May 28, 2020) Mr. A. Pandey (w.e.f February 01, 2022) Mr. B. Akshikar (w.e.f December 1, 2020) Mr. C. Sharma (w.e.f December 1, 2020) Mr. N. Hindia (w.e.f January 4, 2021 upto February 28, 2022) Ms. M. Priyam (upto August 31, 2020) Ms. D. Jakate (upto January 31, 2021) Ms. S. Zota (w.e.f March 23, 2020 upto December 31, 2020) Ms. S. Ghosh(w.e.f August 25, 2020 upto December 1, 2020) # Also member of GSK India Leadership Team 2 The following transactions were carried out with the related parties in the ordinary course of business: (i) Dividend paid to parties referred to in item 1(i) above: ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 Glaxo Group Limited, U.K. 164,62.04 219,49.38 GlaxoSmithKline Pte Limited, Singapore 128,53.09 171,37.45 Eskaylab Limited, U.K. 31,75.20 42,33.60 Burroughs Wellcome International Limited, U.K. 18,14.40 24,19.20 (ii) Details relating to parties referred to in items 1(i) and 1(ii) above: ( ` in lakhs ) Holding Group/ultimate holding Group 1(i) Other companies in the GSK Group 1(ii) Year ended March 31, 2022 Year ended March 31, 2021 Year ended March 31, 2022 Year ended March 31, 2021 1 Purchase of materials/traded goods - - 432,62.26 629,73.24 2 Sale of materials/sale of products (Refer Note 55) - - 74,65.64 9,95.96 3 Purchase of Vaccines business (Refer Note 57) - - 1,66.00 - 4 Purchase of license - - 8,99.82 - 5 Sale of brands and other identified assets (Refer Note 55) - - 1639,84.36 - 6 Expenses recharged to other companies - - 15,95.30 17,62.76 7 Expenses recharged by other companies 7.50 49.56 144,43.40 96,35.07 8 Manufacturing charges recovered - - - 4,31.95 9 Clinical research and data management recoveries - - 6,20.36 9,36.45 10 Interest income on loan given - - 3,19.58 - 11 Loans given - - 190,00.00 - 12 Liabilities written back - - - 77.24 13 Employee benefit liabilities transferred to a related party - - - 19.86 14 Loan receivable from related party - - 190,00.00 - 15 Outstanding receivables at the period end - - 54,82.96 17,74.40 16 Outstanding payables at the period end - 46.17 116,65.46 118,94.44 17 Cross charges recoverable at the period end - - 8,50.00 4.82